TUESDAY, Nov. 15 (HealthDay News) -- A novel treatment known as
whole-body vibration doesn't appear to improve the bone health of
postmenopausal women who are at high risk of developing
The treatment -- which involves standing on a motorized,
vibrating platform in the hope of building bone mass -- showed
promise in animals. But researchers, who hoped those results might
translate to humans, found no benefit for women who used the
platforms for a year, said study co-author Angela M. Cheung, an
internist and director of the osteoporosis program at the
University Health Network, University of Toronto.
"People should use strategies that have been proven" to prevent bone loss and osteoporosis, Cheung said. These include exercise and calcium and vitamin D supplements, she said. The vibrating platform "doesn't do anything, not for bone anyway," she added.
The theory behind whole-body vibration is that the gravitational
force sends signals to bone cells that promote regrowth, leading to
better bone health. Bone deterioration is of special concern to
aging women, half of whom may sustain fractures because bone mass
deteriorates rapidly after menopause, according to the U.S.
National Library of Medicine.
Vibration platforms, which cost about $3,000, have grown in
popularity in recent years. Some health food stores and gyms make
them available to patrons, Cheung said.
In the new study, published in the Nov. 15 issue of
Annals of Internal Medicine, researchers randomly assigned about 200 postmenopausal women to one of three groups. Two groups used a low-magnitude, whole-body vibration platform at one of two speeds for a year, standing on it for 20 minutes a day. The third group did nothing out of the ordinary.
All the women had low bone mass, and all took calcium and
vitamin D supplements. "We wanted to see if (the treatment)
prevented bone loss or could increase bone mass," Cheung said.
After a year, there was no difference in rate of bone loss among
the three groups, the researchers said.
However, Cheung cautioned that it's still unclear whether the
treatment might affect bone in other groups of people, such as
Dr. Joseph Lane, professor of orthopedic surgery at Weill
Medical College of Cornell University, said the study appears valid
and debunks the use of whole-body therapy to treat bone loss.
Currently, he said, bisphosphonate medications such as Fosamax are
the best initial treatment for bone loss, while teriparatide
(Forteo) is an alternative for patients who suffer from side
effects on bisphosphonates.
Patients with osteoporosis are also beginning to take denosumab
(Prolia), an injectable drug approved last year by the U.S. Food
and Drug Administration.
For more on
osteoporosis, visit the U.S. National Library of Medicine.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.